FWFred Were

Fred Were

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fred Were has a total of 236 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The World Health Organization Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns (ACTION-III) trial—rationale for the selected lower steroid dose

    by The Who Action Trials Collaborators, Ebunoluwa Aderonke Adejuyigbe, Olubukola Adeponle Adesina, Salahuddin Ahmed, Shabina Ariff, Adejumoke Idowu Ayede, Rajiv Bahl, Abdullah H. Baqui, Harish Chellani, Saleha Begum Chowdhury, et al.

  • Open Access

    Assessing Neurological Outcomes at One-Year Corrected Age in Preterms ≤34 Weeks Gestation: Research Protocol for a Prospective Cohort Study

    by Florence Murila, Fred Were, Jalemba Aluvaala, Moses Obimbo

    Preterm infants are at high risk of neurodevelopmental disorders, growth faltering, recurrent infections, re-hospitalization, and visual and auditory impairments. Despite the rising burden of preterm births, morbidities and mortalities in sub-Saharan Africa, data on neurodevelopmental and growth outcomes and survival during the first year of life remain scarce. This protocol aims to develop a comprehensive follow-up of care and early screening guidelines for this vulnerable population. The study will determine the prevalence of neurological disabilities at one year of corrected age (CA) among preterm infants (≤34 weeks) discharged from two public hospitals in Nairobi, Kenya. It will identify maternal, neonatal, and clinical factors associated with neurological outcomes, characterize growth patterns and their relationship with neurodevelopmental outcomes and evaluate mortality risk at one year of CA. This prospective cohort will recruit 420 eligible preterm infants and follow them to one-year CA or death. Follow up assessments at 40 weeks’ post-menstrual age (PMA) or 2 weeks post discharge, at 3, 6, 9, and 12 months of CA will document growth, neurodevelopment using the Ages and Stages Questionnaire (ASQ), and sensory outcomes (hearing and visual). Near Infrared Spectroscopy (NIRS) will be performed at one year of CA. Longitudinal analyses using mixed-effects models and generalized estimating equations will examine growth and neurodevelopmental trajectories, while Cox proportional hazards models will assess mortality risk. The study is approved by the Kenyatta National Hospital-University of Nairobi Ethics (KNH-UoN) Committee, Reference Number P466/05/2023. This is the first cohort in Kenya to integrate neurological, growth, and sensory outcomes with advanced imaging in preterm infants. Findings will guide the development of an evidence-based care bundle for comprehensive follow-up and early intervention, potentially improving survival and long-term outcomes for this high-risk population, especially in low-resource settings.

  • Open Access

    Applying a multi-layered, mixed methods approach to evaluate technology and workforce interventions in Kenyan neonatal units

    by Michuki Maina, Sassy Molyneux, Fred Were, Dorothy Oluoch, Edna Mutua, David Gathara, Mike English, Abdulazeez Imam, Gloria Ngaiza, Asma Rababeh, et al.

    Understanding how to best implement healthcare innovations in resource-poor settings requires complex interventions and evaluations, often straining existing healthcare systems. We aimed to address this challenge in our Kenyan neonatal intervention research by deeply integrating stakeholder engagement, applying layered methodologies, and leveraging our research team's diverse expertise. This paper reports on the design and implementation of a research programme examining the impact of new staff introductions on care quality, staff, and family experiences within an existing neonatal technology programme in Kenya. Collaborating with stakeholders, our multidisciplinary programme of research included the analysis of routine health data before and after staff introductions, co-creation of novel quantitative data collection tools, and embedded qualitative research. Continuous feedback from participants, stakeholders, and researchers facilitated an adaptive approach, with timelines and methods adjusted to minimise participant burden. This iterative process allowed for robust data collection to inform health system improvements. Our findings provide insights into implementation and evaluation research for healthcare innovations in resource-constrained settings and emphasise ethical, context-sensitive research practices for sustainable health system strengthening.


  • Open Access

    The World Health Organization Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns (ACTION-III) Trial: study protocol for a multi-country, multi-centre, double-blind, three-arm, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at high probability of late preterm birth in hospitals in low- resource countries

    by Who Action Trials Collaborators, Temitope Adesiji Adegboyega, Ebunoluwa Aderonke Adejuyigbe, Olubukola Adeponle Adesina, Babalola Adeyemi, Salahuddin Ahmed, Francis Akinkunmi, Jalemba Aluvaala, Henry Anyabolu, Shabina Ariff, et al.

    Background: Preterm birth complications are the leading cause of newborn and under-5 mortality. Over 85% of all preterm births occur in the late preterm period, i.e. between 34 and < 37 weeks of gestation. Antenatal corticosteroids (ACS) prevent mortality and respiratory morbidity when administered to women at high risk of an early preterm birth, i.e. < 34 weeks’ gestation. However, the benefits and risks of ACS in the late preterm period are less clear; both guidelines and practices vary between settings. Emerging evidence suggests that the benefits of ACS may be achievable at lower doses than presently used. This trial aims to determine the efficacy and safety of two ACS regimens compared to placebo, when given to women with a high probability of late preterm birth, in hospitals in low-resource countries. Methods: WHO ACTION III trial is a parallel-group, three-arm, individually randomized, double-blind, placebo-controlled trial of two ACS regimens: dexamethasone phosphate 4 × 6 mg q12h or betamethasone phosphate 4 × 2 mg q 12 h. The trial is being conducted across seven sites in five countries—Bangladesh, India, Kenya, Nigeria, and Pakistan. Eligible women are those with a gestational age between 34 weeks 0 days and 36 weeks 5 days, who have a high probability of preterm birth between 12 h and 7 days (up to 36 weeks 6 days gestation). The primary outcome is a composite of stillbirth or neonatal death within 72 h of birth or use of newborn respiratory support within 72 h of birth or prior to discharge from hospital, whichever is earlier. Secondary outcomes include safety and health utilization measures for both women and newborns. The sample size is 13,500 women. Discussion: This trial will evaluate the benefits and possible harms of ACS when used in women likely to have a late preterm birth. It will also evaluate a lower-dose ACS regimen based on literature from pharmacokinetic studies. The results of this trial will provide robust critical evidence on the safe and appropriate use of ACS in the late preterm period internationally. Trial registration: ISRCTN11434567. Registered on 7 June 2021.


  • Open Access

    Does respiratory syncytial virus lower respiratory illness in early life cause recurrent wheeze of early childhood and asthma? Critical review of the evidence and guidance for future studies from a World Health Organization-sponsored meeting

    by Amanda J. Driscoll, S. Hasan Arshad, Louis Bont, Steven M. Brunwasser, Thomas Cherian, Janet A. Englund, Deshayne B. Fell, Laura L. Hammitt, Tina V. Hartert, Bruce L. Innis, et al.


  • Open Access

    Effect of enhancing audit and feedback on uptake of childhood pneumonia treatment policy in hospitals that are part of a clinical network: a cluster randomized trial

    by Philip Ayieko, Grace Irimu, Morris Ogero, Paul Mwaniki, Lucas Malla, Thomas Julius, Mercy Chepkirui, George Mbevi, Jacquie Oliwa, Ambrose Agweyu, et al.

    The World Health Organization (WHO) revised its clinical guidelines for management of childhood pneumonia in 2013. Significant delays have occurred during previous introductions of new guidelines into routine clinical practice in low- and middle-income countries (LMIC). We therefore examined whether providing enhanced audit and feedback as opposed to routine standard feedback might accelerate adoption of the new pneumonia guidelines by clinical teams within hospitals in a low-income setting. In this parallel group cluster randomized controlled trial, 12 hospitals were assigned to either enhanced feedback (n = 6 hospitals) or standard feedback (n = 6 hospitals) using restricted randomization. The standard (network) intervention delivered in both trial arms included support to improve collection and quality of patient data, provision of mentorship and team management training for pediatricians, peer-to-peer networking (meetings and social media), and multimodal (print, electronic) bimonthly hospital specific feedback reports on multiple indicators of evidence guideline adherence. In addition to this network intervention, the enhanced feedback group received a monthly hospital-specific feedback sheet targeting pneumonia indicators presented in multiple formats (graphical and text) linked to explicit performance goals and action plans and specific email follow up from a network coordinator. At the start of the trial, all hospitals received a standardized training on the new guidelines and printed booklets containing pneumonia treatment protocols. The primary outcome was the proportion of children admitted with indrawing and/or fast-breathing pneumonia who were correctly classified using new guidelines and received correct antibiotic treatment (oral amoxicillin) in the first 24 h. The secondary outcome was the proportion of correctly classified and treated children for whom clinicians changed treatment from oral amoxicillin to injectable antibiotics. The trial included 2299 childhood pneumonia admissions, 1087 within the hospitals randomized to enhanced feedback intervention, and 1212 to standard feedback. The proportion of children who were correctly classified and treated in the first 24 h during the entire 9-month period was 38.2% (393 out of 1030) and 38.4% (410 out of 1068) in the enhanced feedback and standard feedback groups, respectively (odds ratio 1.11; 95% confidence interval [CI] 0.37–3.34; P = 0.855). However, in exploratory analyses, there was evidence of an interaction between type of feedback and duration (in months) since commencement of intervention, suggesting a difference in adoption of pneumonia policy over time in the enhanced compared to standard feedback arm (OR = 1.25, 95% CI 1.14 to 1.36, P < 0.001). Enhanced feedback comprising increased frequency, clear messaging aligned with goal setting, and outreach from a coordinator did not lead to a significant overall effect on correct pneumonia classification and treatment during the 9-month trial. There appeared to be a significant effect of time (representing cumulative effect of feedback cycles) on adoption of the new policy in the enhanced feedback compared to standard feedback group. Future studies should plan for longer follow-up periods to confirm these findings. US National Institutes of Health—ClinicalTrials.gov identifier (NCT number) NCT02817971 . Registered September 28, 2016—retrospectively registered.


  • Open Access

    Developing a seasonal influenza vaccine recommendation in Kenya: Process and challenges faced by the National Immunization Technical Advisory Group (NITAG)

    by Jeanette Dawa, Sandra S Chaves, Antoinette Ba Nguz, Rosalia Kalani, Edwina Anyango, Dominic Mutie, Phillip Muthoka, Collins Tabu, Marybeth Maritim, Evans Amukoye, et al.


  • Open Access

    Correlates of isoniazid preventive therapy failure in child household contacts with infectious tuberculosis in high burden settings in Nairobi, Kenya – a cohort study

    by Florence Nafula Okwara, John Paul Oyore, Fred Nabwire Were, Samson Gwer

    Sub-Saharan Africa continues to document high pediatric tuberculosis (TB) burden, especially among the urban poor. One recommended preventive strategy involves tracking and isoniazid preventive therapy (IPT) for children under 5 years in close contact with infectious TB. However, sub-optimal effectiveness has been documented in diverse settings. We conducted a study to elucidate correlates to IPT strategy failure in children below 5 years in high burden settings. A prospective longitudinal cohort study was done in informal settlings in Nairobi, where children under 5 years in household contact with recently diagnosed smear positive TB adults were enrolled. Consent was sought. Structured questionnaires administered sought information on index case treatment, socio-demographics and TB knowledge. Contacts underwent baseline clinical screening exclude TB and/or pre-existing chronic conditions. Contacts were then put on daily isoniazid for 6 months and monitored for new TB disease, compliance and side effects. Follow-up continued for another 6 months. At baseline, 428 contacts were screened, and 14(3.2%) had evidence of TB disease, hence excluded. Of 414 contacts put on IPT, 368 (88.8%) completed the 1 year follow-up. Operational challenges were reported by 258(70%) households, while 82(22%) reported side effects. Good compliance was documented in 89% (CI:80.2–96.2). By endpoint, 6(1.6%) contacts developed evidence of new TB disease and required definitive anti-tuberculosis therapy. The main factor associated with IPT failure was under-nutrition of contacts (p = 0.023). Under-nutrition was associated with IPT failure for child contacts below 5 years in high burden, resource limited settings. IPT effectiveness could be optimized through nutrition support of contacts.


  • Open Access

    Improving skills and institutional capacity to strengthen adolescent immunisation programmes and health systems in African countries through HPV vaccine introduction

    by Carine Dochez, Rosemary J. Burnett, Symplice Mbola Mbassi, Fred Were, Andrew Musyoki, Daisy Trovoada, M. Jeffrey Mphahlele


  • Open Access

    Developing guidelines in low-income and middle-income countries: lessons from Kenya

    by Mike English, Grace Irimu, Rachel Nyamai, Fred Were, Paul Garner, Newton Opiyo

    There are few examples of sustained nationally organised, evidence-informed clinical guidelines development processes in Sub-Saharan Africa. We describe the evolution of efforts from 2005 to 2015 to support evidence-informed decision making to guide admission hospital care practices in Kenya. The approach to conduct reviews, present evidence, and structure and promote transparency of consensus-based procedures for making recommendations improved over four distinct rounds of policy making. Efforts to engage important voices extended from government and academia initially to include multiple professional associations, regulators and practitioners. More than 100 people have been engaged in the decision-making process; an increasing number outside the research team has contributed to the conduct of systematic reviews, and 31 clinical policy recommendations has been developed. Recommendations were incorporated into clinical guideline booklets that have been widely disseminated with a popular knowledge and skills training course. Both helped translate evidence into practice. We contend that these efforts have helped improve the use of evidence to inform policy. The systematic reviews, Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approaches and evidence to decision-making process are well understood by clinicians, and the process has helped create a broad community engaged in evidence translation together with a social or professional norm to use evidence in paediatric care in Kenya. Specific sustained efforts should be made to support capacity and evidence-based decision making in other African settings and clinical disciplines.